FDA approves SYMVESS for extremity vascular trauma with positive results from clinical testing.

From Nasdaq: 2024-12-20 01:42:42

The FDA has approved Humacyte’s SYMVESS for use as a vascular conduit for extremity arterial injury in adults. The approval was based on positive results from the V005 pivotal Phase 2/3 study and real-world evidence from treating wartime injuries in Ukraine. SYMVESS showed high rates of patency and low rates of amputation and infection in clinical testing.



Read more at Nasdaq: FDA Approves SYMVESS To Treat Extremity Vascular Trauma